Nucletron separates from Delft; looks towards half-billion-dollar mark
This article was originally published in Clinica
Executive Summary
Radiation oncology specialist Nucletron has targeted a three-fold increase in revenue within the next five years, following its recent successful spin-off from parent company Delft Instruments. Over the last few years, Delft has been selling many of its non-core subsidiaries in an attempt to focus on the oil and gas industry. This led to Nucletron proposing a management buy-out. The separation, which took effect from July 1, provides Nucletron with its own share capital and allows the company to progress towards a proposed employee-wide shareholding. Nucletron recorded sales of E120m ($165m) in 2006, but since becoming an independent player situated in the top four radiotherapy companies worldwide, the Dutch firm believes it can close the gap on the top three radiotherapy oncology giants Siemens, Elekta and Varian Medical Systems.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.